Of the 91 patients originally diagnosed with PMA, 20 subsequently developed upper motor neuron signs, which would qualify them as having ALS with lower motor neuron onset. Furthermore, upper motor ...

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

Scientists are working on a way to restore the production of a protein that is essential for communication in the brain and ...

A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone disease (also known as ...

A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone ...

A funding boost of more than £78 million will help scientists working to develop a potential treatment for motor neurone ...

An international collaboration led by Flinders University has identified a potential biomarker for amyotrophic lateral sclerosis, also known as Motor Neuron Disease, providing a way to test the ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

This finding challenges the traditional notion that muscle wasting in ALS is a secondary result of motor neuron degeneration—when these neurons don't function normally, muscle cells aren't ...

The condition is a rapidly progressive neurodegenerative disorder leading to wasting, paralysis, and eventual death from respiratory failure.

Progressive muscular atrophy (PMA) is clinically characterized solely by signs of lower motor neuron dysfunction, so patients with this condition are commonly excluded from ALS clinical trials.